Evidence map›Paper›PMID 24376757›Full record

ArticlePloS one2013

Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients.

Karen Cerosaletti, Anya Schneider, Katharine Schwedhelm, Ian Frank, Megan Tatum, Shan Wei, Elizabeth Whalen, Carla Greenbaum, Mariko Kita, Jane Buckner and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Development and function of FOXP3+ regulators of immune responses.Clinical and experimental immunology · 2023
    Article
  15. Article
  16. Clinical and experimental treatment of type 1 diabetes.Clinical and experimental immunology · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Activation pathways that drive CD4Immunological reviews · 2022
    Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Karen CerosalettiTranslational Research, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Anya SchneiderTranslational Research, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Katharine SchwedhelmTranslational Research, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Ian FrankTranslational Research, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Megan TatumTranslational Research, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Shan WeiTranslational Research, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Elizabeth WhalenBioinformatics, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Carla GreenbaumDiabetes Research, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Mariko KitaTranslational Research, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Jane BucknerTranslational Research, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
S Alice LongTranslational Research, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Benaroya Research InstituteVirginia Mason Medical Center · US

Funding

Defining the role of altered cytokine signaling pathways on autoimmunityU01AI101990 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI BUCKNER, JANE HOYT · 2012 to 2016
$12.1M
NIAID NIH HHS AI101990-01NIAID NIH HHS U01 AI101990
6 · The paper itself

Abstract

IL-2 receptor (IL-2R) signaling is essential for optimal stability and function of CD4(+)CD25(hi)FOXP3(+) regulatory T cells (Treg); a cell type that plays an integral role in maintaining tolerance. Thus, we hypothesized that decreased response to IL-2 may be a common phenotype of subjects who have autoimmune diseases associated with variants in the IL2RA locus, including T1D and MS, particularly in cells expressing the high affinity IL-2R alpha chain (IL-2RA or CD25). To examine this question we used phosphorylation of STAT5 (pSTAT5) as a downstream measure of IL-2R signaling, and found a decreased response to IL-2 in CD4(+)CD25(hi) T cells of T1D and MS, but not SLE patients. Since the IL2RArs2104286 haplotype is associated with T1D and MS, we measured pSTAT5 in controls carrying the rs2104286 risk haplotype to test whether this variant contributed to reduced IL-2 responsiveness. Consistent with this, we found decreased pSTAT5 in subjects carrying the rs2104286 risk haplotype. Reduced IL-2R signaling did not result from lower CD25 expression on CD25(hi) cells; instead we detected increased CD25 expression on naive Treg from controls carrying the rs2104286 risk haplotype, and subjects with T1D and MS. However the rs2104286 risk haplotype correlated with increased soluble IL-2RA levels, suggesting that shedding of the IL-2R may account in part for the reduced IL-2R signaling associated with the rs2104286 risk haplotype. In addition to risk variants in IL2RA, we found that the T1D-associated risk variant of PTPN2rs1893217 independently contributed to diminished IL-2R signaling. However, even when holding genotype constant at IL2RA and PTPN2, we still observed a significant signaling defect in T1D and MS patients. Together, these data suggest that multiple mechanisms converge in disease leading to decreased response to IL-2, a phenotype that may eventually lead to loss of tolerance and autoimmunity.

Indexed as

Genetic VariationAdultAllelesAutoimmunityCase-Control StudiesDiabetes Mellitus, Type 1FemaleGene Expression RegulationGenetic Predisposition to DiseaseHaplotypesHumansInterleukin-2Interleukin-2 Receptor alpha SubunitMaleMultiple SclerosisPhenotypeIL2RA protein, humanInterleukin-2Interleukin-2 Receptor alpha SubunitProtein Tyrosine Phosphatase, Non-Receptor Type 2PTPN2 protein, human

Identifiers

PMID24376757
PMCPMC3871703
OpenAlexW1995898275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.